Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Merck & Co. Inc. (NYSE:MRK)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Merck & Co. Inc. for $19.99, or

  • get full access to the entire website for at least 3 months from $49.99.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock

This is a one-time payment. There is no automatic renewal.

Merck & Co. Inc. pages available today for free:

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Beginner level

Merck & Co. Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel LibreOffice Calc
Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Loans payable and current portion of long-term debt
Trade accounts payable
Accrued and other current liabilities
Income taxes payable
Dividends payable
Current liabilities
Long-term debt, excluding current portion
Deferred income taxes
Other noncurrent liabilities
Noncurrent liabilities
Total liabilities
Common stock, $0.50 par value
Other paid-in capital
Retained earnings
Accumulated other comprehensive loss
Treasury stock, at cost
Total Merck & Co., Inc. stockholders’ equity
Noncontrolling interests
Total equity
Total liabilities and equity

Based on: 10-Q (filing date: 2021-05-05), 10-K (filing date: 2021-02-25), 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-05), 10-Q (filing date: 2020-05-06), 10-K (filing date: 2020-02-26), 10-Q (filing date: 2019-11-05), 10-Q (filing date: 2019-08-06), 10-Q (filing date: 2019-05-08), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-06), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-08), 10-K (filing date: 2018-02-27), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-08), 10-Q (filing date: 2017-05-09), 10-K (filing date: 2017-02-28), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-08), 10-Q (filing date: 2016-05-09).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Merck & Co. Inc.’s current liabilities as a percentage of total liabilities and equity increased from Q3 2020 to Q4 2020 but then slightly decreased from Q4 2020 to Q1 2021.
Noncurrent liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Merck & Co. Inc.’s noncurrent liabilities as a percentage of total liabilities and equity decreased from Q3 2020 to Q4 2020 and from Q4 2020 to Q1 2021.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Merck & Co. Inc.’s total liabilities as a percentage of total liabilities and equity increased from Q3 2020 to Q4 2020 but then slightly decreased from Q4 2020 to Q1 2021.
Total Merck & Co., Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Merck & Co. Inc.’s total Merck & Co., Inc. stockholders’ equity as a percentage of total liabilities and equity decreased from Q3 2020 to Q4 2020 but then slightly increased from Q4 2020 to Q1 2021.